Tuberculosis(TB)remains a leading cause of death among infectious diseases,particularly in poor countries.Viral infections,multidrug-resistant and ex-tensively drug-resistant TB strains,as well as the coexistence of c...Tuberculosis(TB)remains a leading cause of death among infectious diseases,particularly in poor countries.Viral infections,multidrug-resistant and ex-tensively drug-resistant TB strains,as well as the coexistence of chronic illnesses such as diabetes mellitus(DM)greatly aggravate TB morbidity and mortality.DM[particularly type 2 DM(T2DM)]and TB have converged making their control even more challenging.Two contemporary global epidemics,TB-DM behaves like a syndemic,a synergistic confluence of two highly prevalent diseases.T2DM is a risk factor for developing more severe forms of multi-drug resistant-TB and TB recurrence after preventive treatment.Since a bidirectional relationship exists between TB and DM,it is necessary to concurrently treat both,and promote recommendations for the joint management of both diseases.There are also some drug-drug interactions resulting in adverse treatment outcomes in TB-DM patients including treatment failure,and reinfection.In addition,autophagy may play a role in these comorbidities.Therefore,the TB-DM comorbidities present several health challenges,requiring a focus on multidisciplinary collaboration and integrated strategies,to effectively deal with this double burden.To effectively manage the comorbidity,further screening in affected countries,more suitable drugs,and better treatment strategies are required.展开更多
The prevention and treatment of neurodegenerative diseases is the new challenge for pharmaceutical industry,but also for public institutions,physicians,patients,and their families.The spread of these pathologies is,in...The prevention and treatment of neurodegenerative diseases is the new challenge for pharmaceutical industry,but also for public institutions,physicians,patients,and their families.The spread of these pathologies is,in fact,a real social problem,especially in the Western Countries where the population age is increasing and chronic diseases are more and more common.展开更多
This book is a testament to the early treatment successes and the hidden challenges of antiretroviral therapy （ART） in resource-poor settings. It is also a wake-up call to the risk of treatment failure and the devel...This book is a testament to the early treatment successes and the hidden challenges of antiretroviral therapy （ART） in resource-poor settings. It is also a wake-up call to the risk of treatment failure and the development of widespread ARV resistance unless all patients are given the continuing support they need to achieve full adherence to ARVs. AIDS is particularly challenging because it requires very high （at least 95%） levels of adherence to prevent treatment failure and the generation of ARV-resistant virus.展开更多
文摘Tuberculosis(TB)remains a leading cause of death among infectious diseases,particularly in poor countries.Viral infections,multidrug-resistant and ex-tensively drug-resistant TB strains,as well as the coexistence of chronic illnesses such as diabetes mellitus(DM)greatly aggravate TB morbidity and mortality.DM[particularly type 2 DM(T2DM)]and TB have converged making their control even more challenging.Two contemporary global epidemics,TB-DM behaves like a syndemic,a synergistic confluence of two highly prevalent diseases.T2DM is a risk factor for developing more severe forms of multi-drug resistant-TB and TB recurrence after preventive treatment.Since a bidirectional relationship exists between TB and DM,it is necessary to concurrently treat both,and promote recommendations for the joint management of both diseases.There are also some drug-drug interactions resulting in adverse treatment outcomes in TB-DM patients including treatment failure,and reinfection.In addition,autophagy may play a role in these comorbidities.Therefore,the TB-DM comorbidities present several health challenges,requiring a focus on multidisciplinary collaboration and integrated strategies,to effectively deal with this double burden.To effectively manage the comorbidity,further screening in affected countries,more suitable drugs,and better treatment strategies are required.
基金Intervento cofinanziato dal Fondo di Sviluppo e Coesione 2007-2013–APQ Ricerca Regione Puglia“Programma regionale a sostegno della specializzazione intelligente e della sostenibilitàsociale ed ambientale-Future In Research”.Project ID:I2PCTF6
文摘The prevention and treatment of neurodegenerative diseases is the new challenge for pharmaceutical industry,but also for public institutions,physicians,patients,and their families.The spread of these pathologies is,in fact,a real social problem,especially in the Western Countries where the population age is increasing and chronic diseases are more and more common.
文摘This book is a testament to the early treatment successes and the hidden challenges of antiretroviral therapy （ART） in resource-poor settings. It is also a wake-up call to the risk of treatment failure and the development of widespread ARV resistance unless all patients are given the continuing support they need to achieve full adherence to ARVs. AIDS is particularly challenging because it requires very high （at least 95%） levels of adherence to prevent treatment failure and the generation of ARV-resistant virus.
